stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) Shares outstanding
Aurinia Pharmaceuticals Inc's shares outstanding at the end of fiscal 2025 was $138.7M, down 5.13% from $146.2M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $135.2M. Over the past ten years it has ranged from $32.2M (fiscal 2015) to $146.2M (fiscal 2024); the current reading is higher than 73% of that period. Aurinia Pharmaceuticals Inc ranks 94th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $138.7M | (5.13%) |
| FY2024 | $146.2M | 2.07% |
| FY2023 | $143.2M | 0.93% |
| FY2022 | $141.9M | 9.70% |
| FY2021 | $129.4M | 9.20% |
| FY2020 | $118.5M | 27.36% |
| FY2019 | $93.0M | 9.72% |
| FY2018 | $84.8M | 10.22% |
| FY2017 | $76.9M | 117.99% |
| FY2016 | $35.3M | 9.74% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $135.2M | 1.23% |
| Jun 2026 | $133.5M | (2.99%) |
| Mar 2026 | $137.6M | (0.76%) |
| Dec 2025 | $138.7M | 1.98% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ADMA ADMA Biologics Inc compare | $225.8M |
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $65.9M |
| VCEL Vericel Corporation compare | $53.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on AUPH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement